Navigation Links
Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
Date:12/6/2012

bodes well for the future success of GLYX-13 and the other promising compounds we have generated from this platform." 

Other NMDA receptor-modulating agents, such as ketamine, have been shown in several human clinical trials to act very rapidly to alleviate the symptoms of depression and bipolar disorder, but their clinical utility has been hampered by their potential for abuse and behavioral impairment, including schizophrenia-like effects at therapeutic doses.

"We are encouraged by these promising data," noted Ronald M. Burch, MD, PhD, Chief Medical Officer of Naurex.  "We have recently begun dosing patients in a GLYX-13 Phase Ilb repeated dose trial, and we are on track to advance our second-generation oral compound, NRX-1074, into clinical trials next year.  Preclinical studies show that our novel NMDA modulators may be applicable to a number of CNS disorders, and we look forward to assessing their potential to address major unmet needs in psychiatry and neurology."

The Phase Ila trial was a randomized, double blind, placebo-controlled study of the efficacy and safety of a single dose of intravenous GLYX-13 in subjects who had failed at least one other antidepressant during the current depressive episode.  It was conducted at 12 clinical centers in the U.S.  Outcome measures included ratings of signs, symptoms and changes in depression scores on standard rating scales for mood and psychiatric disorders.  Independent raters from MedAvante, who were blinded to the protocol, administered certain psychiatric assessments for the trial to ensure the quality and objectivity of the screening and rating data.  Safety was also assessed.

Naurex's CNS programs are based on the work of company founder, Joseph R. Moskal, PhD, and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.

The 51st Annual Meeting of the American College of Neuropsychopharmacology i
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
8. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
9. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
(Date:12/19/2014)... Fayetteville, Arkansas (PRWEB) December 18, 2014 ... plans to locate its pilot production facility and ... further develop and produce innovative new materials that ... was chosen not only because of its historic, ... regional leaders’ efforts to attract leading edge, technology-based ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... biomaterial market will grow moderately through 2023 as the ... growing awareness of dental biomaterials all spur procedure volumes. ... as China and ... dental procedures within reach for a larger proportion of ...
Breaking Biology Technology:Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3
... May 13 A guide to BRCA1 and ... resource is designed to equip physicians and other healthcare professionals who are ... the complexities of BRCA1/2 gene testing. , ... According to the American Cancer Society, ...
... TIANJIN, China , May 13 /PRNewswire-Asia/ -- A ... of,Biotechnology and Medicine (TJAB) and Genzyme Corporation was held in the,Tianjin ... , , ... executives including Rao Zihe, President of TJAB and,President of Nankai University, ...
... May 13  Fibrocell Science, Inc. (OTC Bulletin ... of autologous cell therapies for aesthetic, medical and scientific ... study (IT-H-001) of azficel-T, an autologous cell therapy currently ... (FDA) for the treatment of moderate to severe nasolabial ...
Cached Biology Technology:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 2Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 3
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Geology articles this month are open access: "Steady ... during fault slip: Evidence from the rock record." Other ... whale "intestinal products" in central Italy to flooding as ... new findings via the Compact Reconnaissance Imaging Spectrometer for ...
... fatal case of potato poisoning: James B. Matheney of Vandalia, ... tubers, which had turned green due to sunlight exposure. Two ... wife, two daughters and four sons -- showed symptoms of ... the potatoes, and a breast-fed baby boy. His wife, aged ...
... years ago, two former Stanford University postdoctoral fellows, one ... the Harvard Stem Cell Institute (HSCI) in Cambridge, began ... healthy blood cells. What was it, they asked, that ... And after almost a decade of bicoastal collaboration, ...
Cached Biology News:Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 2Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 3Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 4Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 5Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 6Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 7Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 8Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 9Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 10Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 11Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 12Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 13Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 14Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 15The pathway to potato poisons 2Cross-country collaboration leads to new leukemia model 2Cross-country collaboration leads to new leukemia model 3
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
Biology Products: